Tuberculosis (TB) continues to cause more deaths worldwide than any other single
infectious disease. Even though tuberculosis appears to be decreasing in incidence globally …

Background Treatment success rates for multidrug-resistant tuberculosis (MDR-TB) remain
low globally. Availability of newer drugs has given scope to develop regimens that can be …

Two new drugs—bedaquiline and delamanid—have recently been approved by stringent
regulatory authorities to treat multidrug-resistant tuberculosis (TB) and recommended by the …

Background The Médecins Sans Frontières Clinic in Mumbai, India, has been providing
concomitant bedaquiline (BDQ) and delamanid (DLM) in treatment regimen for patients with …

Drug-resistant tuberculosis (DR-TB) remains a global crisis due to the increasing incidence
of drug-resistant forms of the disease, gaps in detection and prevention, models of care, and …

Acquired Resistance to Bedaquiline and Delamanid in Therapy for Tuberculosis | New England
Journal of Medicine Skip to main content The New England Journal of Medicine homepage …

Background Bedaquiline and delamanid have been approved for treatment of multidrug-
resistant (MDR) tuberculosis in the past 5 years. Because of theoretical safety concerns …

We report the experiences of 5 patients taking bedaquiline with delamanid in combination: 1
patient was cured; 3 culture converted, with 2 continuing and 1 changing therapy; and 1 died …

Antimicrobial resistance is a major public health problem globally. Likewise, forms of
tuberculosis (TB) resistant to first-and second-line TB medicines present a major challenge …

Background Bedaquiline is used as a substitute for second-line injectable (SLI) intolerance
in the treatment of multidrug-resistant (MDR) tuberculosis, but the efficacy and safety of this …